Video

Dr. Shah on Excitement With Venetoclax in Patients With MCL

Author(s):

Bijal D. Shah, MD

In Partnership With:

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the potential with venetoclax (Venclexta) in patients with mantle cell lymphoma (MCL).

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the potential with venetoclax (Venclexta) in patients with mantle cell lymphoma (MCL).

Venetoclax is definitely a novel therapy on the horizon in MCL, Shah explains, especially given that data from a phase I study have shown a 75% overall response rate. These are the types of response rates on ibrutinib that got researchers excited about ibrutinib, he adds. It should be stated that none of the patients were ibrutinib-resistant on that trial. However, there is clearly activity.

Additionally, ibrutinib plus venetoclax in MCL is a combination that the community should pay attention to. While there will be more myeloid toxicity with that regimen, it is likely to significantly prolong event-free survival.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Related Content
Tom van Meerten, MD, PhD, hematologist, Department of Hematology, University Medical Center Groningen
January 6th 2025

ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Mantle cell lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 18th 2024

Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL

Andrew Kuykendall, MD
October 16th 2023

FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

Myelofibrosis | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 18th 2024

Acalabrutinib Regimen Demonstrates Efficacy in De Novo Mantle Cell Lymphoma

Mantle Cell Lymphoma | stock.adobe.com
December 17th 2024

Glofitamab Produces Durable Remissions in R/R Mantle Cell Lymphoma